相关实验视频
Updated: Jun 11, 2025

08:25
Identification of Circular RNAs using RNA Sequencing
Published on: November 14, 2019
12.1K
为循环RNA疗法开发一个增强的嵌合物变的内子-外子系统.
Lei Wang1,2,3, Chunbo Dong1,2,4, Weibing Zhang4
1MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.
Theranostics
|September 30, 2024
概括
研究人员开发了一种通用嵌合式变异性内子-外子 (CPIE) 系统,以改善循环RNA (circRNA) 治疗生产. 这种高效的系统增强了circRNA合成,并证明了针对瘤和病毒的强大疫苗开发的潜力.
科学领域:
- 生物技术和基因工程 生物技术和基因工程
- 在RNA治疗方面,RNA疗法.
- 疫苗开发 疫苗开发
背景情况:
- 循环RNAs (circRNAs) 由于其稳定性和持续的蛋白质翻译,对治疗有希望.
- 目前RNA循环化效率的局限性阻碍了用于临床用途的纯化circRNAs的大规模制造.
- 一个通用和高效的circRNA合成系统对于推进基于circRNA的疗法至关重要.
研究的目的:
- 开发一种通用且高效的RNA循环化系统,用于合成circRNA生产.
- 评估合成的circRNAs的翻译能力和免疫性.
- 评估基于circRNA的疫苗对癌症和病毒感染的体内疗效.
主要方法:
- 基于工程自剪接内子的嵌合式变内子-外子 (CPIE) 系统的开发.
- 使用高性能液态染色学 (HPLC) 和大小排除染色学净化circRNAs.
- 将编码HPV E7或SARS-CoV-2 dRBD的circRNA封装成脂质纳米粒子 (LNP),用于疫苗配方.
- 在小鼠模型中通过抗原特异性T和B细胞反应评估体内疗效.
主要成果:
- 成功设计了一个通用CPIE系统,提高RNA循环化效率.
- 纯化的circRNAs表现出较低的免疫性和持续强大的蛋白质表达.
- 在体内研究证实,circRNA疫苗在小鼠中引起了针对瘤和SARS-CoV-2点的强有力的免疫激活.
结论:
- 开发的CPIE系统为体外circRNA合成提供了一种高效和通用的方法.
- 这个系统对开发新型circRNA疗法和疫苗具有重大潜力.
- 该研究表明,使用circRNAs作为有效的疫苗平台的可行性.
相关概念视频
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
piRNA - Piwi-interacting RNAs
6.8K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
6.8K
Alternative RNA Splicing
21.0K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.0K

